Moderna Vaccine Claims 94% Efficacy Against Coronavirus
The US-based pharma company said it expects to have around 20 million doses ready to be shipped with US by the end of the year
United States biotechnology giant Moderna announced on Monday that its work in progress COVID19 vaccine is 94% effective against the virus. This is the second major breakthrough after another developer, Pfizer confirmed last week that its inoculation had an efficacy of 90%.
The early results of Moderna’s trials were released after 30,000 participants were tested. 95 of these volunteers developed COVID19 on whom the vaccine was used, and the preliminary results shared.
Developed along with the US National Institutes of Health, the immunisation is a two-shot dose administered 28 days apart. The injection can be stored in a regular refrigerator. It requires only -20 degrees centigrade storage temperature for a period of six months.
Meanwhile, the indigenous Covaxin developed by Bharat Biotech has entered its third phase of clinical human trials. The shot developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) will be administered on 26,000 patients as a part of its final stage testing.
Catch all the latest trending news only on ZEE5